Form 4: Veracyte Director Sells Shares Under Pre-Arranged Trading Plan

Veracyte, Inc. Director Karin Eastham reported the sale of 4,590 shares of common stock on June 13, 2025, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Karin Eastham, a Director of Veracyte, Inc. (VCYT), reported a transaction involving the company's common stock.
• On June 13, 2025, Ms. Eastham disposed of 4,590 shares of Veracyte common stock.
• The shares were sold at a weighted average price of $26.664 per share, with individual sale prices ranging from $26.39 to $26.92.
• Following this transaction, Karin Eastham beneficially owns 13,907 shares of Veracyte common stock directly.
• The transaction was executed pursuant to a Rule 10b5-1 plan, which was adopted by Ms. Eastham on August 20, 2024.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While an insider sale can be perceived negatively, the fact that it was executed under a pre-arranged Rule 10b5-1 plan significantly mitigates any negative implications, indicating a planned diversification or liquidity event rather than a reaction to new negative information.

Positives

• The transaction was conducted under a Rule 10b5-1 plan, adopted on August 20, 2024, which indicates a pre-scheduled sale and mitigates concerns about opportunistic insider trading.

Negatives

• A director's sale of shares, even if pre-planned, can sometimes be perceived as a lack of confidence in the company's near-term prospects or a signal of personal diversification.

Risks

• While executed under a 10b5-1 plan, the sale by a director could be interpreted by some investors as a negative signal regarding the company's future performance or valuation, potentially leading to short-term stock price volatility.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic outlook, as it is solely a report of an insider's securities transaction.

Industry Context

This specific Form 4 filing reports an individual insider transaction and does not provide broader industry context or trends. It reflects a director's personal portfolio management rather than a company-wide strategic move.

Corporate Governance

Related Party Transactions

• This is an insider transaction by a director, which is a form of related party dealing, specifically the sale of common stock by Karin Eastham, a director of Veracyte, Inc.

Stakeholder Impact

• Shareholders: May interpret the director's sale as a signal, though the 10b5-1 plan suggests it's a pre-planned event rather than a reaction to new information. The sale could contribute to minor downward pressure on the stock price in the short term.

Key Dates

Keywords

Veracyte, VCYT, Insider Trading, Form 4, Stock Sale, Karin Eastham, Director, Rule 10b5-1 Plan